Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays

Cancer Research

Volumn 67, Issue 12, 2007, Pages 5635-5642

  French, Pim J ^a   Peeters, Justine ^a   Horsman, Sebastiaan ^a   Duijm, Elza ^a   Siccama, Ivar ^a   Van Den Bent, Martin J ^a   Luider, Theo M ^a   Kros, Johan M ^a   Van Der Spek, Peter ^a   Sillevis Smitt, Peter A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BRAIN TUMOR; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION PROFILING; GLIAL BRAIN TUMOR; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BRAIN NEOPLASMS; EXONS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLIOMA; HUMANS; IN SITU HYBRIDIZATION; PROTEIN ISOFORMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 34250795169     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2869     Document Type: Article

References (44)

1. Legler JM, Ries LA, Smith MA, et al. Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 1999;91:1382-90.
2. Macdonald DR. New frontiers in the treatment of malignant glioma. Semin Oncol 2003;30:72-6.
3. Kleihues P, Cavenee WK. World Health Organization Classification of Tumours of the Nervous System. Lyon: WHO/IARC; 2000.
4. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
5. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol Berl 2005;109:93-108.
6. Grabowski PJ, Black DL. Alternative RNA splicing in the nervous system. Prog Neurobiol 2001;65:289-308.
7. Nagane M, Lin H, Cavenee WK, Huang HJ. Aberrant receptor signaling in human malignant gliomas: mechanisms and therapeutic implications. Cancer Lett 2001;162 Suppl:S17-21.
8. 1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 1998;12:3675-85.
9. Mellinghoff IK, Wang MY, Vivanco I, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005;353:2012-24.
10. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000;60:1383-7.
11. Shi E, Kan M, Xu J, Wang F, Hou J, McKeehan WL. Control of fibroblast growth factor receptor kinase signal transduction by heterodimerization of combinatorial splice variants. Mol Cell Biol 1993;13:3907-18.
12. Wang F, Kan M, Yan G, Xu J, McKeehan WL. Alternately spliced NH2-terminal immunoglobulin-like Loop I in the ectodomain of the fibroblast growth factor (FGF) receptor 1 lowers affinity for both heparin and FGF-1. J Biol Chem 1995;270:10231-5.
13. Chunduru S, Kawami H, Gullick R, Monacci WJ, Dougherty G, Cutler ML. Identification of an alternatively spliced RNA for the Ras suppressor RSU-1 in human gliomas. J Neurooncol 2002;60:201-11.
14. Simon M, Koster G, Ludwig M, et al. Alternative splicing of the p15 cdk inhibitor in glioblastoma multiforme. Acta Neuropathol Berl 2001;102:167-74.
15. Uno M, Oba-Shinjo SM, de Aguiar PH, et al. Detection of somatic TP53 splice site mutations in diffuse astrocytomas. Cancer Lett 2005;224:321-7.
16. Xu X, Joh HD, Pin S, et al. Expression of multiple larger-sized transcripts for several genes in oligodendrogliomas: potential markers for glioma subtype. Cancer Lett 2001;171:67-77.
17. Hui L, Zhang X, Wu X, et al. Identification of alternatively spliced mRNA variants related to cancers by genome-wide ESTs alignment. Oncogene 2004;23:3013-23.
18. French PJ, Swagemakers SMA, Nagel JHA, et al. Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res 2005;65:11335-44.
19. Schroeder A, Mueller O, Stocker S, et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006;7:3.
20. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004;350:1617-28.
21. Mischel PS, Cloughesy TF, Nelson SF. DNA-micro-array analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci 2004;5:782-92.
22. Rickman DS, Bobek MP, Misek DE, et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 2001;61:6885-91.
23. Godard S, Getz G, Delorenzi M, et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res 2003;63:6613-25.
24. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63:1602-7.
25. Freije WA, Castro-Vargas FE, Fang Z, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004;64:6503-10.
26. Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A 2005;102:5814-9.
27. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
28. Ule J, Ule A, Spencer J, et al. Nova regulates brain-specific splicing to shape the synapse. Nat Genet 2005;37:844-52.
29. Xu Q, Modrek B, Lee C. Genome-wide detection of tissue-specific alternative splicing in the human transcriptome. Nucleic Acids Res 2002;30:3754-66.
30. Yeo G, Holste D, Kreiman G, Burge CB. Variation in alternative splicing across human tissues. Genome Biol 2004;5:R74.
31. Pan Q, Shai O, Misquitta C, et al. Revealing global regulatory features of mammalian alternative splicing using a quantitative microarray platform. Mol Cell 2004;16:929-41.
32. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003;72:291-336.
33. Kalnina Z, Zayakin P, Silina K, Line A. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 2005;42:342-57.
34. Graveley BR. Sorting out the complexity of SR protein functions. RNA 2000;6:1197-211.
35. Frederick L, Eley G, Wang XY, James CD. Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. Neuro-oncol 2000;2:159-63.
36. Johnson JM, Castle J, Garrett-Engele P, et al. Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 2003;302:2141-4.
37. Yeakley JM, Fan JB, Doucet D, et al. Profiling alternative splicing on fiber-optic arrays. Nat Biotechnol 2002;20:353-8.
38. Zhu J, Shendure J, Mitra RD, Church GM. Single molecule profiling of alternative pre-mRNA splicing. Science 2003;301:836-8.
39. Fehlbaum P, Guihal C, Bracco L, Cochet O. A microarray configuration to quantify expression levels and relative abundance of splice variants. Nucleic Acids Res 2005;33:e47.
40. Nagao K, Togawa N, Fujii K, et al. Detecting tissue-specific alternative splicing and disease-associated aberrant splicing of the PTCH gene with exon junction microarrays. Hum Mol Genet 2005;14:3379-88.
41. O'Connor V, Genin A, Davis S, et al. Differential amplification of intron-containing transcripts reveals long term potentiation-associated up-regulation of specific Pde10A phosphodiesterase splice variants. J Biol Chem 2004;279:15841-9.
42. Chen FC, Chen CJ, Ho JY, Chuang TJ. Identification and evolutionary analysis of novel exons and alternative splicing events using cross-species EST-to-genome comparisons in human, mouse and rat. BMC Bioinformatics 2006;7:136.
43. Nekrutenko A. Identification of novel exons from rat-mouse comparisons. J Mol Evol 2004;59:703-8.
44. Frey BJ, Mohammad N, Morris QD, et al. Genomewide analysis of mouse transcripts using exon microarrays and factor graphs. Nat Genet 2005;37:991-6.